Review
doi: 10.1146/annurev.pharmtox.41.1.237.
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence
Affiliations
- PMID: 11264457
- DOI: 10.1146/annurev.pharmtox.41.1.237
Item in Clipboard
Review
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence
Annu Rev Pharmacol Toxicol.
2001.
Abstract
In spite of its proven heuristic value, the dopamine hypothesis of schizophrenia is now yielding to a multifactorial view, in which the other monoamines as well as glutamate and GABA are included, with a focus on neurotransmitter interactions in complex neurocircuits. The primary lesion(s) in schizophrenia does not necessarily involve any of these neurotransmitters directly but could deal with a more general defect, such as a faulty connectivity of developmental origin. Nevertheless, a precise identification of neurotransmitter aberrations in schizophrenia will probably provide clues for a better understanding of the disease and for the development of new treatment and prevention strategies.
Similar articles
-
Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.Med Hypotheses. 2012 May;78(5):594-600. doi: 10.1016/j.mehy.2012.01.035. Epub 2012 Feb 13. Med Hypotheses. 2012. PMID: 22336089
-
Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?Biol Psychiatry. 2009 Jun 15;65(12):1003-5. doi: 10.1016/j.biopsych.2009.04.006. Biol Psychiatry. 2009. PMID: 19481640 No abstract available.
-
[A biochemical theory of schizophrenia].Nervenarzt. 1984 Nov;55(11):602-6. Nervenarzt. 1984. PMID: 6151120 German.
-
Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.Clin Ther. 2005;27 Suppl A:S16-24. doi: 10.1016/j.clinthera.2005.07.017. Clin Ther. 2005. PMID: 16198197 Review.
-
The biological basis of schizophrenia: new directions.J Clin Psychiatry. 1997;58 Suppl 10:22-7. J Clin Psychiatry. 1997. PMID: 9265913 Review.
Cited by
-
Central Nervous System Medications: Pharmacokinetic and Pharmacodynamic Considerations for Older Adults.Drugs Aging. 2024 Jun;41(6):507-519. doi: 10.1007/s40266-024-01117-w. Epub 2024 May 30. Drugs Aging. 2024. PMID: 38814377 Free PMC article. Review.
-
Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.Biomedicines. 2023 Jul 13;11(7):1977. doi: 10.3390/biomedicines11071977. Biomedicines. 2023. PMID: 37509616 Free PMC article. Review.
-
Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function.Front Psychiatry. 2023 May 19;14:1180720. doi: 10.3389/fpsyt.2023.1180720. eCollection 2023. Front Psychiatry. 2023. PMID: 37275985 Free PMC article.
-
Lipopolysaccharide Exacerbates Ketamine-Induced Psychotic-Like Behavior, Oxidative Stress, and Neuroinflammation in Mice: Ameliorative Effect of Diosmin.J Mol Neurosci. 2023 Mar;73(2-3):129-142. doi: 10.1007/s12031-022-02077-9. Epub 2023 Jan 18. J Mol Neurosci. 2023. PMID: 36652038
-
The Neuromodulatory Role of the Noradrenergic and Cholinergic Systems and Their Interplay in Cognitive Functions: A Focused Review.Brain Sci. 2022 Jul 7;12(7):890. doi: 10.3390/brainsci12070890. Brain Sci. 2022. PMID: 35884697 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
